Answers are grounded in this paper and cite their sources.
Intestinal fibrosis is a major complication of inflammatory bowel disease, and it can lead to fixed strictures, intestinal obstruction, and repeated surgical intervention. Although effective control of inflammation may limit ongoing tissue injury, no approved therapy selectively prevents or reverses established intestinal fibrosis. This therapeutic gap reflects an incomplete understanding of the cellular and metabolic mechanisms that sustain fibrotic remodeling. In this review, we integrate classical extracellular-matrix pathways with recent single-cell, spatial, and metabolic evidence to provide a multicellular framework for intestinal fibrogenesis. Single-cell studies indicate that intestinal fibroblasts comprise overlapping and environmentally responsive states rather than fixed lineages. Their activation is shaped by reciprocal communication with immune cells, epithelial and endothelial cells, smooth muscle cells, creeping fat, and the intestinal microbiota. Metabolic reprogramming provides an additional layer of regulation through glycolysis, pentose phosphate pathway, glutamine–proline metabolism, lactate-associated signaling, and extracellular metabolite sensing. However, the strength of evidence varies among these mechanisms, and direct links between defined fibroblast states and specific metabolic dependencies remain limited. In this review, we further discuss therapeutic opportunities targeting immune–stromal communication, pathogenic fibroblast programs, cellular metabolism, extracellular-matrix turnover, and mechanotransduction. Translating these opportunities into stage-specific interventions will require spatially resolved functional models to validate causal targets and fibrosis-selective biomarkers to assess therapeutic effects.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: